Chrysalis Bio Therapeutics

Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company based in Galveston, Texas, dedicated to developing and commercializing innovative treatments for serious respiratory disorders and acute radiation exposure. Their groundbreaking research focuses on utilizing natural regenerative peptides to restore vascular function and activate normal stem cell populations in the body, accelerating tissue repair and preventing the damaging effects of trauma, disease, ischemia, and radiation exposure.

With a strong emphasis on TP508 peptide technology, Chrysalis aims to address critical medical needs such as acute respiratory distress syndrome (ARDS), brain cancer, respiratory failure, and nuclear radiation exposure. Their novel peptide drug product, TP508, has shown promising results in reducing neural inflammation, restoring neural stem cells, mitigating vascular damage, hemorrhage, and inflammation, and increasing survival rates. Through their cutting-edge research and clinical trials, Chrysalis BioTherapeutics is at the forefront of revolutionizing medical treatments and saving lives through innovation.

Generated from the website